Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.41 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.41 |
| ▸ | TYMP | P19971 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21158798 | 0.85 | SLC6A11 (0.43) | SLC6A2SLC6A4SLC6A3SLC6A1SLC6A11 | |
| SCHEMBL27414176 | 0.85 | SLC6A11 (0.43) | SLC6A2SLC6A4SLC6A3SLC6A1SLC6A11 | |
| SCHEMBL12651813 | 0.81 | TYMP (0.43) | L3MBTL1SLC6A1SLC6A11TYMPMEN1 | |
| SCHEMBL27414202 | 0.81 | SLC6A11 (0.38) | L3MBTL1SLC6A1SLC6A11TYMPLTA4H | |
| SCHEMBL2567526 | 0.80 | MEN1 (0.57) | SLC6A1SLC6A11TYMPMEN1KMT2A | |
| SCHEMBL27056605 | 0.80 | MEN1 (0.57) | SLC6A1SLC6A11TYMPMEN1KMT2A | |
| SCHEMBL2567523 | 0.80 | MEN1 (0.57) | SLC6A1SLC6A11TYMPMEN1KMT2A | |
| SCHEMBL12515630 | 0.78 | HPGD (0.48) | L3MBTL1SLC6A1SLC6A11MEN1KMT2A | |
| SCHEMBL13190443 | 0.78 | SLC6A11 (0.40) | SLC6A2SLC6A4SLC6A3SLC6A1SLC6A11 | |
| SCHEMBL25764406 | 0.74 | MEN1 (0.39) | SLC6A1SLC6A11TYMPMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183355-B2 | Method for the synthesis of oligonucleotide derivatives | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2012-05-22 | — | — | US | disclosed |
| US-20110245478-A1 | Method for the Synthesis of Oligonucleotide Derivatives | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245478-A1 | Method for the Synthesis of Oligonucleotide Derivatives | MSN, RNGTT, DCLRE1B | L3MBTL1 2018/4885SLC6A2 3092/4885SLC6A4 2146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.